Your browser doesn't support javascript.
loading
Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina; Sarti, Samanta; Giannecchini, Laura; Lubrano, Simone; Marranci, Andrea; Evangelista, Monica; Peppicelli, Silvia; Ippolito, Chiara; Barravecchia, Ivana; Guzzolino, Elena; Montagnani, Valentina; Gowen, Michael; Mercoledi, Elisa; Mercatanti, Alberto; Comelli, Laura; Gurrieri, Salvatore; Wu, Lawrence W; Ope, Omotayo; Flaherty, Keith; Boland, Genevieve M; Hammond, Marc R; Kwong, Lawrence; Chiariello, Mario; Stecca, Barbara; Zhang, Gao; Salvetti, Alessandra; Angeloni, Debora; Pitto, Letizia; Calorini, Lido; Chiorino, Giovanna; Pellegrini, Marco; Herlyn, Meenhard; Osman, Iman; Poliseno, Laura.
Afiliação
  • Vitiello M; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Tuccoli A; Institute of Clinical Physiology (IFC), CNR, Pisa, Italy.
  • D'Aurizio R; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Sarti S; Laboratory of Integrative Systems Medicine (LISM), Institute of Informatics and Telematics (IIT), CNR, Pisa, Italy.
  • Giannecchini L; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Lubrano S; University of Siena, Italy.
  • Marranci A; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Evangelista M; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Peppicelli S; University of Siena, Italy.
  • Ippolito C; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Barravecchia I; University of Siena, Italy.
  • Guzzolino E; Institute of Clinical Physiology (IFC), CNR, Pisa, Italy.
  • Montagnani V; Section of Experimental Pathology and Oncology, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy.
  • Gowen M; Unit of Histology, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • Mercoledi E; Scuola Superiore Sant'Anna, Pisa, Italy.
  • Mercatanti A; Scuola Superiore Sant'Anna, Pisa, Italy.
  • Comelli L; Tumor Cell Biology Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUC, Firenze, Italy.
  • Gurrieri S; New York University, New York, NY, USA.
  • Wu LW; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Ope O; Institute of Clinical Physiology (IFC), CNR, Pisa, Italy.
  • Flaherty K; Institute of Clinical Physiology (IFC), CNR, Pisa, Italy.
  • Boland GM; Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUP, Pisa, Italy.
  • Hammond MR; The Wistar Institute, Philadelphia, PA, USA.
  • Kwong L; The Wistar Institute, Philadelphia, PA, USA.
  • Chiariello M; Massachusetts General Hospital, Boston, MA, USA.
  • Stecca B; Massachusetts General Hospital, Boston, MA, USA.
  • Zhang G; Massachusetts General Hospital, Boston, MA, USA.
  • Salvetti A; MD Anderson Cancer Center, Houston, TX, USA.
  • Angeloni D; Institute of Clinical Physiology (IFC), CNR, Pisa, Italy.
  • Pitto L; Signal Transduction Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUS, Siena, Italy.
  • Calorini L; Tumor Cell Biology Unit, Core Research Laboratory, Istituto Toscano Tumori (ITT), AOUC, Firenze, Italy.
  • Chiorino G; The Wistar Institute, Philadelphia, PA, USA.
  • Pellegrini M; Unit of Experimental Biology and Genetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • Herlyn M; Scuola Superiore Sant'Anna, Pisa, Italy.
  • Osman I; Institute of Clinical Physiology (IFC), CNR, Pisa, Italy.
  • Poliseno L; Section of Experimental Pathology and Oncology, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy.
Oncotarget ; 8(15): 25395-25417, 2017 Apr 11.
Article em En | MEDLINE | ID: mdl-28445987
ABSTRACT
Despite increasing amounts of experimental evidence depicting the involvement of non-coding RNAs in cancer, the study of BRAFV600E-regulated genes has thus far focused mainly on protein-coding ones. Here, we identify and study the microRNAs that BRAFV600E regulates through the ERK pathway.By performing small RNA sequencing on A375 melanoma cells and a vemurafenib-resistant clone that was taken as negative control, we discover miR-204 and miR-211 as the miRNAs most induced by vemurafenib. We also demonstrate that, although belonging to the same family, these two miRNAs have distinctive features. miR-204 is under the control of STAT3 and its expression is induced in amelanotic melanoma cells, where it acts as an effector of vemurafenib's anti-motility activity by targeting AP1S2. Conversely, miR-211, a known transcriptional target of MITF, is induced in melanotic melanoma cells, where it targets EDEM1 and consequently impairs the degradation of TYROSINASE (TYR) through the ER-associated degradation (ERAD) pathway. In doing so, miR-211 serves as an effector of vemurafenib's pro-pigmentation activity. We also show that such an increase in pigmentation in turn represents an adaptive response that needs to be overcome using appropriate inhibitors in order to increase the efficacy of vemurafenib.In summary, we unveil the distinct and context-dependent activities exerted by miR-204 family members in melanoma cells. Our work challenges the widely accepted "same miRNA family = same function" rule and provides a rationale for a novel treatment strategy for melanotic melanomas that is based on the combination of ERK pathway inhibitors with pigmentation inhibitors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Amelanótico / MicroRNAs / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Amelanótico / MicroRNAs / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália